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INTRODUCTION
It is now well established that a key requirement for 
invasion and metastasis of cancer cells is the degradation 
of both the extracellular matrix (ECM) that surrounds the 
tumor and the basement membrane which presents the final 
barrier between the tumor cells and the blood stream [1–5]. 
Degradation of the ECM facilitates invasion of tumor 
cells into the organ parenchyma, whereas degradation of 
the basement membrane is required for their entry into the 
blood stream as well as their metastasis to distant organs. 
Cancer cells that have acquired an invasive phenotype 
release proteases that attack and digest the protein 
component of the matrix that would restrict the movement 
of these malignant cells. These proteases, including 
the urokinase-type plasminogen activator (uPA) [6, 7], 
cathepsin B [8] and matrix metalloproteinases (MMPs) [9], 
have been the subject of intense study in recent years as 
potential mediators of cancer cell invasion and metastasis. 
For example, multiple studies have demonstrated that 
the expression of uPA is directly linked to tumor cell 
invasiveness and metastasis [10–13]. Importantly, uPA 
expression in both the tumor and the surrounding stroma 
has been shown to be a prognostic indicator of survival in 
various cancers with high expression being associated with 
poor prognosis [5, 14–17]. 
Cell surface protease activation during RAS transformation: 
Critical role of the plasminogen receptor, S100A10
Patricia A. Madureira1, Alamelu G. Bharadwaj2, Moamen Bydoun3, Katy Garant3, 
Paul O'Connell2, Patrick Lee3, David M. Waisman2,3
1Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
2Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada
3Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada
Correspondence to: David Waisman, email: david.waisman@dal.ca
Keywords: S100A10, RAS, plasminogen, plasmin, annexin A2
Received: February 22, 2016    Accepted: June 12, 2016    Published: June 24, 2016
ABSTRACT
The link between oncogenic RAS expression and the acquisition of the invasive 
phenotype has been attributed to alterations in cellular activities that control 
degradation of the extracellular matrix. Oncogenic RAS-mediated upregulation 
of matrix metalloproteinase 2 (MMP-2), MMP-9 and urokinase-type plasminogen 
activator (uPA) is critical for invasion through the basement membrane and 
extracellular matrix. The uPA converts cell surface-bound plasminogen to plasmin, 
a process that is regulated by the binding of plasminogen to specific receptors on 
the cell surface, however, the identity of the plasminogen receptors that function 
in this capacity is unclear. We have observed that transformation of cancer cells 
with oncogenic forms of RAS increases plasmin proteolytic activity by 2- to 4-fold 
concomitant with a 3-fold increase in cell invasion. Plasminogen receptor profiling 
revealed RAS-dependent increases in both S100A10 and cytokeratin 8. Oncogenic 
RAS expression increased S100A10 gene expression which resulted in an increase 
in S100A10 protein levels. Analysis with the RAS effector-loop mutants that interact 
specifically with Raf, Ral GDS pathways highlighted the importance of the RalGDS 
pathways in the regulation of S100A10 gene expression. Depletion of S100A10 from 
RAS-transformed cells resulted in a loss of both cellular plasmin generation and 
invasiveness. These results strongly suggest that increases in cell surface levels 
of S100A10, by oncogenic RAS, plays a critical role in RAS-stimulated plasmin 
generation, and subsequently, in the invasiveness of oncogenic RAS expressing 
cancer cells.
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The uPA is secreted from cells as an inactive 
proenzyme, pro-uPA, which binds to the cell surface via 
its cell surface receptor, uPAR. The latter is associated 
with the external surface of the plasma membrane 
by a glycosyl phosphatidylinositol (GPI) anchor, and 
functions to localize pro-uPA to the cell surface where it 
is activated to form the active serine protease, uPA. The 
uPA cleaves plasminogen, generating the active protease 
plasmin. Plasmin is a broad specificity serine protease. 
It degrades fibrin in blood clots (fibrinolysis) and other 
substrates, including components of the extracellular 
matrix and basement membranes such as type IV collagen, 
fibronectin and laminin [18–20]. Plasmin also activates 
MMPs including pro-MMP-1, –3, –7, –9, –10, and –13, 
resulting in further breakdown of the ECM [21, 22]. The 
plasminogen that serves as a substrate for uPA is localized 
to the cell surface due to its interaction with specific 
plasminogen receptors [23–28]. 
S100A10 is a key plasminogen receptor that 
binds to the cell surface via its cell surface receptor, 
annexin A2 [29, 30]. The S100A10/annexin A2 
complex colocalizes with the uPA/uPAR complex 
thereby localizing plasmin generation to the cell surface 
[31, 32]. S100A10 regulates between 50–90% of the 
plasmin generation of a number of normal and cancer 
cells (reviewed in [24, 33]). The first link between 
plasminogen receptors and oncogenic transformation 
of cells was the report that S100A10 was upregulated 
by the oncogene responsible for acute promyelocytic 
leukemia (APL), PML-RARα [34]. These studies 
showed that expression of PML-RARα resulted in 
enhanced plasmin activity and increased cell surface 
expression of S100A10. When PML-RARα expressing 
cells were depleted of S100A10 and expression of PML-
RARα initiated, plasmin generation was dramatically 
decreased. Thus, S100A10 was shown to be directly 
regulated by and to play a critical role in the stimulation 
of plasmin generation by the PML-RARα oncoprotein.
The acquisition of activating mutations in the RAS 
gene family results in the progression of precancerous 
cells to malignancy. The expression of the oncogenic 
RAS protein, one of the earliest oncogenic events in 
many cancers, also increases the expression of pro-uPA 
and uPAR [35, 36]. This RAS-dependent activation of 
uPA/uPAR is thought to account, in part, for increases 
in cellular proteolytic activity, although a link between 
RAS- dependent transformation and increased cellular 
plasmin proteolytic activity has not been directly 
demonstrated. In the current report, we have investigated 
the regulation of plasminogen receptors by oncogenic 
RAS and their relationship to RAS-dependent changes 
in plasmin generation and cellular invasion. This study 
identifies for the first time, the plasminogen receptor, 
S100A10, as a key link between RAS-dependent oncogenic 
transformation of cells and RAS-dependent increases in 
plasmin proteolytic activity and cancer cell invasion. 
RESULTS
Expression of oncogenic RAS stimulates cellular 
plasmin generation
The link between oncogenic RAS expression and the 
acquisition of the invasive phenotype has been attributed 
to alterations in cellular activities that regulate the 
degradation of the extracellular matrix (reviewed in [37]). 
Although the RAS-dependent regulation of the MMPs 
and cathepsin B has been well established [37–39], it 
has not been clear to what extent plasmin activity is 
regulated by oncogenic RAS. In order to determine if 
RAS transformation affects cellular plasmin generation, 
we transfected HEK 293 cells with an empty vector 
(HEK-293-pBABE control) or with the oncogenic HRAS 
(G12V) mutant (HEK-293-HRAS) and measured plasmin 
generation. Since expression of oncogenic RAS can 
increase the release of the plasminogen activator, urokinase-
type plasminogen activator (uPA), cells were assayed both 
in the presence and absence of exogenous uPA. As shown 
in Figure 1A, expression of oncogenic HRAS results in a 
three-fold increase in plasmin proteolytic activity in the 
presence of exogenous uPA and a five-fold increase in 
plasmin proteolytic activity in the absence of exogenous 
uPA. We also observed that expression of oncogenic HRAS 
increased plasmin proteolytic activity by about 2-fold in 
293T and NIH-3T3 cell lines (Figure 1B, 1C). Furthermore, 
the expression of wild-type HRAS or oncogenic KRAS 
also increased plasmin proteolytic activity (Supplementary 
Figure S1). A RAS-GTP pulldown assay and subsequent 
western blot analysis confirmed increased RAS activity 
in RAS-transfected cell lines (Supplementary Figure S2). 
These data establish that expression of different members 
of the RAS family increases cellular plasmin generation in 
several cell lines. 
Oncogenic RAS-dependent activation of 
plasminogen is mediated by a plasminogen 
receptor with a carboxyl-terminal lysine
Plasmin generation results from the interaction 
of plasminogen activators with cell surface bound 
plasminogen. Although a single receptor has been 
extensively characterized for uPA, namely uPAR, 
multiple plasminogen receptors have been identified 
on the surface of normal and transformed cells [25, 26, 
40, 41]. Mechanistically, the binding of plasminogen 
to its cell surface receptors involves the interaction 
of the plasminogen kringle domains with lysine 
residues of plasminogen receptors [27, 28, 42, 43]. It 
is generally accepted that plasminogen receptors with 
carboxyl- terminal lysine residues are most effective 
in both plasminogen binding and subsequent plasmin 
generation although internal lysines have also been 
shown to interact with plasminogen [44, 45]. We 
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observed that pretreatment of cells with the lysine 
mimetic, ε-aminocaproic acid (ε-ACA), which binds 
to and blocks the interaction of the plasminogen kringle 
domains with plasminogen receptors, inhibited plasmin 
generation by control and H-RAS transformed HEK-
293 (Figure 2A) and 293T cells (Figure 2B) by better 
than 80%. This established the importance of the lysine-
binding regions of the plasminogen kringle domains in 
plasmin generation. We also observed that removal of the 
extracellular carboxyl- terminal lysine residues from cell 
surface receptor proteins, by pretreatment of cells with 
carboxypeptidase B, resulted in a significant reduction in 
plasmin generation by HEK-293 cells (Figure 2A), thus 
highlighting the importance of plasminogen receptors 
with carboxyl-terminal lysines in the RAS-stimulated 
generation of plasmin. Pretreatment of cells with the 
plasmin inhibitor, aprotinin resulted in a similar reduction 
in plasmin generation as carboxypeptidase B treatment. 
Furthermore, regardless of whether plasmin activity was 
stimulated by oncogenic HRAS, KRAS or wild-type 
HRAS, RAS- dependent plasmin generation was blocked by 
ε-ACA further confirming a key role for the lysine residues 
of the plasminogen receptor(s) in RAS-dependent plasmin 
generation (Figure 2 and Supplementary Figure S1).
Plasmin plays a key role in RAS-dependent 
cellular invasiveness
The initial step in the metastatic cascade is the 
activation of local tumor cell invasion, a process that has 
been termed invasive escape and that relies on the ability 
of cancer cells to break away from the primary tumor 
[11, 12]. The link between oncogenic RAS expression 
and the acquisition of the invasive phenotype has been 
attributed to the increased expression and/or activity 
of various proteases, including plasmin. Although the 
induction of uPA expression by oncogenic RAS has 
been well established, the direct role that oncogenic 
Figure 1: The expression of oncogenic Ras activates cellular plasmin generation. HEK 293 (A), 293T (B), NIH-3T3 
(C) were transduced with either empty vector retrovirus (pBabe control), or oncogenic HRAS G12V expressing retrovirus (HRASG12V) and 
incubated with 1 µM glu-plasminogen and 50 nM uPA for 10 minutes before the addition of 500 µM plasmin substrate S2251. The rate of 
plasmin generation was determined from the slope of the A405 nm vs time2 progress curve (N = 6). Statistical analysis was performed by 
Student´s t-test.
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RAS plays in plasmin generation has not been studied in 
detail. Interestingly, we observed that although HRAS-
dependent transformation of cells did not influence 
cellular migration when fetal bovine serum (FBS) was 
used as a chemoattractant (Figure 3A–3C), invasion 
through a Matrigel barrier was dramatically stimulated 
by expression of HRAS G12V (Figure 3D–3F). In 
order to investigate the role of the carboxyl-terminal 
containing plasminogen receptors in invasion, we 
treated control and HRAS-transformed HEK-293 cells 
with ε-ACA or carboxypeptidase B. These treatments 
resulted in a significant loss in both RAS-dependent 
and RAS-independent invasion and this effect was 
mirrored when the plasmin activity of the invading cells 
was inhibited with aprotinin (Figure 3D). Oncogenic 
HRAS mediates the upregulation of MMP2 and MMP9 
which play a key role in degrading the extracellular 
matrix [37]. Consistent with those reports, we observed 
that the broad-spectrum MMP inhibitor, GM6001 also 
inhibited both RAS-independent and RAS-dependent 
invasion (Figure 3D). This result is also consistent with 
the fact that plasmin activates several MMPs and this 
mechanism is important in plasmin induced invasion. 
These data highlight, for the first time, the significant 
role that plasminogen receptors play in RAS-dependent 
cellular invasion.
Figure 2: Mechanism of plasmin generation at the cell surface of oncogenic RAS expressing cells. Plasmin generation was 
measured for (A), HEK 293 or (B), 293T cells transduced with either empty vector retrovirus (pBabe control) or oncogenic HRAS G12V 
expressing retrovirus (HRASG12V) and stably selected with puromycin. Cells were either plated in 96 well plates for two days (HEK 293) 
before assay or released with enzyme free cell dissociation buffer and plated in 96 well plates in suspension for the assay (293T). Cells were 
either mock treated or treated with aprotinin (Ap) (2.2 μM), ϵ-ACA (100 mM) or carboxypeptidase B (CpB) (5U/ml) as indicated. The cells 
were washed 3 times with incubation buffer (Hanks balanced salt solution containing 3 mM CaCl
2
 and 1 mM MgC
l2
) and incubated with 
0.5 µM glu-plasminogen for 20–30 minutes with or without aprotinin and ϵ-ACA before the addition of 500 µM plasmin substrate S2251. 
For the CpB treatments, cells were incubated with or without CpB for 30 minutes and washed three times before the addition of 0.5 µM 
glu-plasminogen. The rate of plasmin generation was determined from the slope of the A405 nm vs min2 progress curve (N = 4). Statistical 
analysis was performed by two-way ANOVA.
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Regulation of plasminogen receptors by 
oncogenic RAS 
Plasminogen receptors are a heterogeneous group 
of cell surface proteins whose expression accounts for 
the total plasminogen-binding capacity of the cell with 
approximately 105–107 binding sites per cell [27, 46]. 
Of the plasminogen receptors, enolase-1 [43, 47], 
cytokeratin 8 [48, 49], HMGB1[45, 50], Plg-Rkt [51], 
S100A4 [52], S100A10 [29, 30] and histone H2B [53] are 
the most intensively studied. As shown in Figure  
4, of these plasminogen receptors, only cytokeratin 8 
and S100A10 (and its binding partner, ANXA2) were 
increased after oncogenic HRAS expression in HEK 
293 cells. As observed for plasmin activity, it was noted 
that expression of wild-type HRAS or oncogenic KRAS 
also resulted in elevated levels of S100A10 and ANXA2 
(Figure 4). However, the effect of RAS on cytokeratin 8 
was not observed in all cell lines examined as 293T cells 
transfected with oncogenic HRAS failed to show an 
increased expression of cytokeratin 8, whereas S100A10 
and annexin A2 expression were elevated in these cells 
(Supplementary Figure S3). Cytokeratin 8 expression 
has been reported on the surface of cancer cells and 
only in certain epithelial cells [48, 54–56] and to be 
upregulated in HRAS expressing epidermal cells [57]. 
Nonetheless, the loss of cytokeratin 8 expression rather 
than its upregulation is associated with metastasis and 
chemoresistance [58]. In contrast, S100A10, a carboxyl-
terminal lysine-containing plasminogen receptor has been 
shown to account for the generation of as much as 90% of 
the cell surface plasmin generation [24, 33] and has been 
shown to play an important role in both tumor growth 
and metastasis [31, 32]. Therefore, considering the well-
established role of S100A10 in plasmin generation we 
focused our subsequent studies on S100A10.
Figure 3: Enhanced plasmin generation plays a major role in oncogenic RAS-dependent cell invasion. HEK 293 
(A, D), 293T (B, E), or NIH-3T3 (C, F) cells were transduced with either empty vector retrovirus (pBabe control) or oncogenic HRAS 
G12V expressing retrovirus (HRASG12V). Cells were plated on the upper chamber of uncoated chambers (A–C) or Matrigel (MTG)-coated 
chambers (D–F) and incubated in serum free medium containing 0.5 μM plasminogen, in the presence or absence of aprotinin (10 µM), 
ε-ACA (100 mM), CpB (5 U/ml) or GM6001 (10 µM), as indicated. The lower chamber contained medium with fetal bovine serum (FBS) 
as a chemoattractant. Invading cells were quantified according to the manufacturer›s instructions. Data are expressed as mean number 
of cells per 40× field (10 fields/experimental condition) plus or minus SD of 4 independent wells. Statistical analysis was performed by 
Student´s t-test.
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Regulation of S100A10 expression by oncogenic 
RAS 
Our data suggested that S100A10 was regulated by 
oncogenic RAS and might be at least partially responsible 
for the oncogenic RAS-dependent increases in cellular 
plasmin generation. S100A10 is present on the cell 
surface as a heterotetrameric complex with its binding 
partner, ANXA2 which aids in tethering S100A10 to 
the membrane (reviewed in [59]). We observed that 
both S100A10 and its binding partner, ANXA2, were 
upregulated in a variety of cells expressing oncogenic 
HRAS (Figure 5A). This increase in total levels of 
S100A10 and ANXA2 was observed on the extracellular 
surface of HRASG12V expressing cells (Figure 5B–5D). 
One of the most well established mouse models 
of pancreatic cancer is the inducible-Ras (iKRas) mouse 
model. This model system allows tissue-specific, inducible 
and reversible expression of mutant KRas [60]. The 
iKRas mice develop pancreatic cancer that is dependent 
on sustained iKRas activity. Using the pancreatic cancer 
cells isolated from iKRas tumors we interrogated the 
relationship between iKRas and S100A10. We observed 
that activation of the expression of iKRas in these cells 
resulted in a dramatic increase in expression of S100A10 
(Supplementary Figure S4).
Expression of oncogenic RAS is a common feature 
of many cancers particularly pancreatic, lung, colon, 
sarcomas among others. In order to determine if there 
was a relationship between oncogenic RAS expression 
Figure 4: Regulation of plasminogen receptor expression by RAS. Transfected HEK 293 cells expressing empty vector (pBabe 
control), wild type HRAS (HRAS WT), oncogenic HRAS G12V (HRASG12V) or oncogenic KRAS G12D (KRASG12D) were selected and 
cultured for two weeks. The stably transfected cells were plated and cultured for two to three days, then lysed in lysis buffer containing 
protease and phosphatase inhibitors. Following lysis, the protein concentration was determined using Bradford reagent. The total protein 
(20–30 μg) was separated in 10–20% gradient gel, and transfered to a nitrocellulose membrane. The membrane was probed with primary 
antibodies as indicated and subsequently probed with IR-dye conjugated secondary antibodies, and scanned using the Li-COR Odyssey 
imager. 
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and S100A10 levels in clinically relevant cancer cells, 
we analyzed by western blotting, a panel of different 
cancer cell lines of which some express oncogenic 
RAS (Supplementary Figure S5). Our results showed a 
significant correlation between oncogenic RAS expression 
and S100A10 levels. For example, we observed that the 
oncogenic KRAS expressing breast cancer cell line 
MDA MB 231 showed much higher levels of S100A10 
compared to MCF7 breast cancer cells (that do not express 
oncogenic RAS).
To further investigate the S100A10 levels in 
clinically relevant cancer cell lines, we depleted KRAS 
from A549 (lung cancer) and MiaPaca2 (pancreatic 
cancer) cells and analysed S100A10 expression by 
western blotting (Supplementary Figure S6A, S6B). These 
results showed a significant downregulation of S100A10 
in KRAS-depleted cells compared to control cells. 
Interestingly, within the pools of cells that did not show 
downregulation of KRAS, we did not observe decreased 
expression of S100A10. These results further confirm the 
regulation of S100A10 protein levels by oncogenic RAS.
A region of the RAS protein referred to as the 
effector domain has been shown to be essential for 
the interaction between RAS-GTP and several of its 
downstream effectors. Effector loop mutations alter the 
ability of HRAS to activate the Raf1 (V12S35RAS) vs 
PI3K (V12C40RAS) vs RalGDS (V12G37RAS) signaling 
pathways and preferentially activate one pathway but not 
the others [61].The effector domain mutants of oncogenic 
HRAS were tested for a possible role in the regulation 
of S100A10 protein levels. As shown in Figure 6A, 
S100A10 protein expression was activated by all three 
effector mutants whereas annexin A2 protein levels were 
unaffected by the effector mutants in HEK293 cells. In 
contrast, in NIH3T3 cells, the V12S35RAS mutant that 
selectively activates Raf1 failed to increase S100A10 
protein levels (Figure 6B). This suggested that the PI3K 
and RalGDS pathways contributed to enhanced S100A10 
protein levels in both cell lines but only in the HEK 293 
cells did the Raf1 pathway contribute to expression of 
S100A10 protein levels. This observation was consistent 
with other studies suggesting that RAS signaling exhibits 
significant cell context variations [62].
Semi-quantitative RT-PCR (qRT-PCR) analysis 
showed that oncogenic RAS activated S100A10 
gene expression but not annexin A2 gene expression 
(Figure 6C, 6D). Furthermore, in both HEK 293 and NIH 
3T3 cells, HRASV12G37 a mutant that predominately 
activates the RAS/RalGDS pathway, stimulated S100A10 
gene expression, implicating the importance of the 
RalGDS pathway in the regulation of S100A10 expression 
(Figure 6B, 6C). To further verify that oncogenic RAS 
affected transcription of the S100A10 gene, HEK 293 cells 
were transfected with the luciferase reporter construct 
pGL4-S100A10. HEK 293 V12HRAS cells showed a 
four-fold increase in p11 promoter activity compared to 
HEK 293 pBABE cells indicating that RAS-responsive 
elements are contained within the S100A10 promoter 
(Figure 6E).
S100A10 plays a key role in oncogenic RAS-
dependent plasmin generation
Although our data suggested that RAS-dependent 
transformation of cells increased plasmin generation 
and cellular invasiveness concomitant with an increase 
in S100A10 levels it was unclear if this relationship was 
causal or coincidental. This question was approached by 
depleting S100A10 levels from RAS-transformed cells 
and measuring both plasmin generation and cellular 
invasiveness. Depletion of S100A10 did not affect the 
levels of other plasminogen receptors (Supplementary 
Figure S7). We observed that the depletion of S100A10 
(Figure 7A) resulted in a significant loss of both RAS-
dependent increases in plasmin generation (Figure 7B) and 
cellular invasiveness (Figure 7C), therefore establishing 
that S100A10 is responsible for much of the increases in 
plasmin generation and cellular invasion that are activated 
upon RAS transformation. 
DISCUSSION
The first committed step in metastasis, the 
departure of tumor cells from a solid malignant tumor 
is controlled by three events, namely: 1) the attachment 
to and interaction of the tumor cells with components 
of the ECM and basement membrane: 2) the activation 
of tumor cell migration and: 3) the activation of local 
proteolysis. Increased extracellular protease activity is one 
of the distinguishing features of metastatic cells. Proteases 
facilitate the invasion of malignant/metastatic cells by 
promoting the degradation of basement membranes and 
stromal ECM thereby facilitating their intravasation into 
the blood and/or lymph vessels. Evidence has accumulated 
that different types of tumor-associated proteases as well 
as their inhibitors and receptors are all involved in tumor 
invasion and metastasis. However, of the many oncogenic 
proteins that drive transformation, mutations that lead to 
constitutively active RAS and its associated activation of 
downstream signaling molecules have been implicated 
in approximately 30% of all human cancers [63]. In this 
regard, oncogenic RAS-mediated upregulation of MMP2, 
MMP9, and cathepsin B has been shown to be particularly 
important in stimulating cancer cell proteolytic activity 
and invasion [37]. The introduction of oncogenic RAS into 
cells increases extracellular protease activity in general and 
the expression of uPAR in particular [64–69]. In the current 
study, we investigated the relationship between expression 
of oncogenic RAS and activation of plasmin proteolytic 
activity at the cell surface of cancer cells. We observed 
that expression of oncogenic RAS results in a substantial 
increase in cellular plasmin generation in a number of cell 
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lines suggesting that this phenomenon is a common feature 
of RAS-transformed cancer cells. We also demonstrate the 
fundamental role of the plasminogen receptor, S100A10 
in RAS-dependent cellular plasmin generation. A model 
conceptualizing our data is provided in Figure 8.
The uPA and uPAR are expressed in almost every 
malignant solid tumor studied to date, while most normal 
tissues express little or none. The uPA is overexpressed 
by most aggressive tumor phenotypes and the expression 
of uPA and uPAR is regulated by both growth factors 
Figure 5: Oncogenic RAS stimulates S100A10 protein expression. HEK 293, 293T, NIH-3T3 and MCF7 cells were transduced 
with either empty vector retrovirus (pBabe control) or oncogenic HRAS G12V expressing retrovirus (HRASG12V). (A) 20 μg of each total 
cell extract was subjected to SDS-PAGE followed by western blotting with the antibodies indicated. (B) 293T and MCF7 pBabe control 
or HRASG12V cells were incubated with PBS containing 20 mM EGTA to elute the cell surface bound S100A10-ANXA2 complex. Cells 
were centrifuged at 1000 g for 5 minutes and elutes containing cell surface S100A10 were stored. Cell pellets containing intracellular 
S100A10 were lysed. 20 μg of each total cell extract and equivalent amounts of each eluted sample were subjected to SDS-PAGE followed 
by western blotting with the antibodies indicated. Quantification of protein bands was performed with the LI-COR Odyssey scanner 
software; (C) HEK 293 or (D)293T pBabe control or HRASG12V transduced cells were incubated with S100A10 and ANXA2 antibodies, 
after which a secondary FITC-labeled antibody was added. Cells were washed two times with PBS containing Ca2+ and S100A10 (p11) 
and ANXA2 (p36)  cell surface protein expression was analyzed by FACS. 
Oncotarget47728www.impactjournals.com/oncotarget
Figure 6: Mechanism of regulation of S100A10 expression. HEK 293 and NIH-3T3 cells were transduced with either empty vector 
retrovirus (pBabe control), oncogenic HRAS G12V expressing retrovirus (HRASG12V), oncogenic HRAS S35 mutant (HRASV12S35), 
oncogenic HRAS C40 mutant (HRASV12C40) or oncogenic HRAS G37 mutant (HRASV12G37). (A) 20 μg of each total cell extract 
was subjected to SDS-PAGE followed by western blotting with the antibodies indicated. (B) 20 μg of each total cell extract from HEK 
293 or NIH-3T3 pBabe control, HRASG12V, HRAS V12S35, HRAS V12C40 or HRAS V12G37 was subjected to SDS-PAGE followed by western 
blotting with the antibodies indicated; (C, D) RNA from HEK 293 (C) or NIH 3T3 (D) cells transduced with empty vector retrovirus 
(pBabe control), oncogenic HRAS G12V expressing retrovirus (HRASG12V), oncogenic HRAS S35 mutant (HRASV12S35), oncogenic 
HRAS C40 mutant (HRASV12C40) or oncogenic HRAS G37 mutant (HRASV12G37) was isolated by Trizol RNA extraction; cDNA was 
generated and the mRNA expression level for ANXA2 and S100A10 was measured by qRT-PCR as described in materials and methods. 
The mRNA expression levels were normalized to GAPDH mRNA using the 2-ΔΔCT method and are represented as ratio of RAS transformed 
over non-transformed cells. Error bars represent the standard deviation obtained from at least three independent studies performed with 
triplicate samples. (E) HEK 293 pBabe control and HEK 293 HRAS G12V expressing cells were co-transfected with pGL4.22-S100A10 
full-length promoter and pRSV-Renilla (transfection control) at a 50:1 ratio. Luciferase promoter assay was performed according to the 
manufacturer’s instructions (Dual Luciferase promoter assay, Promega). Error bars represent the standard deviation obtained from five 
independent experiments with at least triplicate samples each. Statistical analysis was performed by Student´s t-test.
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and oncogenes. Clinical studies have revealed that high 
expression levels of uPA and uPAR correlate with poor 
patient prognosis and outcome. It is well established that 
uPA stimulates cellular proteolytic activity by converting 
the zymogen plasminogen into the active serine protease 
plasmin. It was initially reported that both uPAR levels 
and laminin degradation were decreased in HCT 116 
cells in which the KRAS oncogene had been ‘knocked 
out’ by homologous recombination [35]. More recently, 
Quigley and coworkers highlighted the critical importance 
of the uPA/plasmin system in the ability of tumor cells 
to intravasate into the blood vessels. They directly 
demonstrated that inhibition of plasmin activity resulted 
in a loss in tumor cell invasiveness in vivo [11]. These 
and other studies have presented the possibility that the 
observed increased plasmin activity demonstrated by cells 
expressing oncogenic RAS results from RAS-dependent 
increases in uPA and/or uPAR. However, we observed 
that compared to control cells, RAS-transformed cells had 
a greater capacity to generate plasmin in the presence of 
saturating amounts of exogenous uPA. Since the control 
and RAS-transformed cells had equivalent amounts of 
uPA, and under these conditions the RAS-transformed 
cells still generated much more plasmin than the control 
cells, the simplest explanation for this result is that RAS-
transformed cells upregulate their plasminogen receptors 
which then results in a substantial increase in plasmin 
generation. This suggestion contrasts with other models 
Figure 7: The S100A10 plasminogen receptor plays a major role in oncogenic RAS-dependent plasminogen activation. 
(A) 293T cells stably expressing empty vector (pBabe control) or oncogenic HRAS G12V (HRASG12V) were transfected with 4 μM of pre-
designed siRNA (Ambion) specific for S100A10 (S100A10 siRNA) and a non-silencing siRNA control (siRNA control) using Lipofectamine 
2000 transfection reagent as per manufacturer’s instructions (Invitrogen). Cell lysates were prepared 48 hours after transfection, and total 
levels of S100A10 and RAS were examined by Western blotting. (B) 48 hours after transfection, 25,000 cells were plated in 96 well plates 
and incubated overnight. Cells were washed 3 times with incubation buffer (Hanks balanced salt solution containing 3 mM CaCl
2
 and 
1 mM MgCl
2
) and incubated with 0.5 µM glu-plasminogen for 20–30 minutes before the addition of 500 µM plasmin substrate S2251. 
The rate of plasmin generation was measured from the A405 nm vs min2 progress curves (N = 4). (C) 48 hours after transfection, 100,000 
cells were plated on the upper chamber of matrigel coated inserts (BD Biosciences) and incubated in serum free medium containing 0.5 
μM plasminogen for 48 hours. The lower chamber contained medium with 10% fetal bovine serum (FBS) as a chemoattractant. Invading 
cells were fixed with methanol and stained with Hematoxylin and Eosin. Cells were quantified by manual counting using a light microscope 
(20X). Data are expressed as mean number of cells invading per 20× field (5 fields/experimental condition) in duplicates. The plot is 
representative of three independent experiments. Statistical analysis was performed by two-way ANOVA with Tukey test of significance.
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in which increased secretion of uPA accounts for increased 
plasmin generation by RAS-transformed cells. Clearly, 
identification of the plasminogen receptors that participate 
in RAS-dependent increases in plasmin generation is of 
importance in understanding the molecular mechanisms 
involved in metastasis.
Our observation that ε-ACA and carboxypeptidase 
B, two treatments that are known to block plasminogen 
binding to the cell surface [42, 43] resulted in the total 
loss of RAS-dependent plasmin generation by several 
cancer cell lines is a paradigm shift in that it establishes 
that plasminogen receptors are necessary for plasmin 
generation by RAS-transformed cancer cells. Furthermore, 
our data also suggests that plasminogen receptors that 
possess a carboxyl-terminal lysine play the key role 
in RAS-dependent plasmin generation. Numerous cell 
surface molecules are capable of binding plasminogen, 
thereby facilitating its conversion into plasmin [43]. The 
majority of these cell membrane plasminogen receptors 
possess carboxyl-terminal lysines, which allow them 
to function as plasminogen receptors via direct binding 
of their carboxyl-terminal lysine to the lysine-binding 
sites located in the kringle domains of plasminogen. The 
identity of the key plasminogen receptors participating in 
the activation of uPA-dependent plasmin generation have 
not been determined. In order to identify the plasminogen 
receptors that participate in RAS-dependent plasmin 
generation, we investigated if transformation of cells 
with oncogenic RAS affected the expression of the well 
characterized plasminogen receptors, namely, enolase, 
histone H2B, cytokeratin 8, PlgRkt , HMGB1, S100A10 
and S100A4. Our study established, for the first time, 
that only cytokeratin 8 and S100A10 protein levels are 
increased in HEK 293 cells expressing oncogenic RAS. 
In contrast, S100A10 but not cytokeratin 8 expression was 
increased in 293T cells. However, unlike S100A10, the 
loss of cytokeratin 8 is known to facilitate the increased 
migration and invasiveness of epithelial cancer cells [58]. 
Therefore, it is difficult to envision a role for cytokeratin 
8 in invasion and metastasis.
Figure 8: Proposed model for S100A10 dependent regulation of plasmin activity in RAS transformed cells. Oncogenic 
RAS up-regulates S100A10 and uPAR mRNA levels via the Ral-GDS/Ral pathway leading to increased expression of these proteins. Newly 
synthesized uPAR protein undergoes glycosylation in the endoplasmic reticulum and is shuttled to the cell surface. Newly synthesized 
S100A10 associates with its binding partner ANXA2 forming the ANXA2-S100A10 heterotetramer (AIIt). Both uPAR and AIIt localize 
in caveolae lipid rafts at the cell surface. Secreted uPA forms a complex with uPAR while the plasminogen present in the extracellular 
fluid forms a complex with the S100A10 subunit of AIIt. Plasmin generation is stimulated due to co-localization of the uPA/uPAR and 
plasminogen/AIIt complexes. The increased plasmin generation contributes to the overall proteolytic activity of the RAS-transformed cells 
which results in increased cellular invasiveness
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Depletion of S100A10 in oncogenic RAS 
expressing cells established that S100A10 is a key 
plasminogen receptor involved in plasmin activation and 
in the promotion of the enhanced invasive phenotype 
observed in RAS transformed cells. Although other 
reports had previously identified the uPA/uPAR system as 
important effectors of RAS induced cell invasiveness, the 
plasminogen receptor(s) involved in cell surface plasmin 
generation were still unknown. We had previously shown 
that the S100A10/ANXA2 heterotetramer co-localizes 
with uPAR at the cell surface. Here we show for the first 
time that S100A10 plays a main role in RAS-induced 
plasmin formation and invasion.
We also sought to determine the mechanism by 
which oncogenic RAS up-regulates S100A10 protein. 
Since we observed that S100A10 mRNA was upregulated 
and the S100A10 promoter was stimulated by oncogenic 
RAS transformation, we have concluded that S100A10 
is transcriptionally regulated by oncogenic RAS. When 
in the GTP-bound state, RAS is capable of binding 
to several different established and potential effector 
proteins, including members of the Raf, PI(3)K and 
RalGDS families. To examine which of these pathways 
regulated S100A10 expression, we transfected cells with 
RAS effector loop mutants. Certain point mutations in the 
RAS effector loop region (amino acids 32 to 40 in HRAS) 
render HRAS defective for binding specific effector 
proteins while remaining competent for binding and 
activating others, albeit at lower than wild-type efficiency 
[61, 70]. We observed that the HRASV12G37, a mutant 
that predominately activates the RAS/RalGDS pathway, 
stimulated S100A10 gene expression, implicating the 
importance of the RalGDS pathway in the transcriptional 
regulation of S100A10. Interestingly, the RalGEF pathway 
has been shown to significantly contribute to RAS-
initiated metastasis in cellular systems [71]. S100A10 
protein level was also increased in HRASV12C40 
expressing cells even though this mutant HRAS did not 
induce S100A10 gene transcription. This result suggests 
that the PI3K pathway might be involved in increasing 
the stability of the S100A10 protein by a still unknown 
mechanism. It is therefore reasonable to speculate that 
activation of S100A10-dependent plasmin generation may 
contribute to the metastatic phenotype observed in these 
model systems.
S100A10 was originally identified as a potent 
activator of plasmin generation in vitro [29, 30] that bound 
tPA (0.45 μM), plasminogen (1.8 μM) and plasmin (0.36 
μM) [72]. Subsequent studies showed that S100A10 could 
account for between 50–90% of the plasmin generation 
by a number of cells (reviewed in [33]). S100A10 is 
overexpressed in animal tumor model systems and in 
human cancer, where it correlates with a poor prognosis 
and chemotherapeutic resistance [73–80]. In various 
animal tumor model systems, the inhibition of S100A10 
expression, or activity, decreases tumor growth and 
metastasis [31, 32]. Mutations of the KRAS gene occur 
in over 90% of pancreatic carcinomas. S100A10 levels 
are increased in patients with pancreatic cancer [80]. 
Furthermore, using both immunohistochemical analysis 
and quantitative proteomics of patient tumors it has been 
demonstrated that S100A10 levels were unchanged in 
pancreatitis, but dramatically increased in late stage 
pancreatic intraepithelial neoplasia lesions and in pancreatic 
ductal adenocarcinoma lesions. These patient data 
highlight the potential importance of S100A10 in KRAS-
driven pancreatic cancer. Interestingly, we also observed 
that activation of KRas in mouse pancreatic cancer 
cells resulted in the increased expression of S100A10 
(Supplementary Figure S4). Aberrant activation of the RAS 
pathway due to mutations in the RAS GTPase activating 
protein is ubiquitous in human liver cancer and this 
unrestrained activation of wild-type RAS is a key feature 
of hepatocarcinogenesis [81]. In the present report we 
show a significant relationship between oncogenic KRAS 
expression and enhanced levels of S100A10 in a panel of 
different human cancer cell lines. It was striking to observe 
that cells derived from cancers that show high mutational 
rates for KRas, such as colon (HCT 116), lung (A549) 
and pancreatic (MiaPaca2) cancers, have high levels 
of expression of S100A10 (Supplementary Figure S5). 
Interestingly, we also observed that the breast cancer cell 
line MDA MB 231 that expresses oncogenic KRAS (which 
is not a commonly acquired mutation in this type of cancer) 
shows higher levels of expression of S100A10 compared 
to the breast cancer cell line MCF7 that express WT 
KRAS (Supplementary Figure S5). To further confirm that 
KRAS activity is important for the regulation of S100A10 
expression in cancer cells derived from human tumors, we 
depleted KRAS from A549 and MiaPaca2 cells. This data 
showed a significant downregulation of S100A10 in these 
cells (Supplementary Figure S6), supporting the concept 
that KRAS activity plays a key role in regulating S100A10 
levels in cancer cells.
S100A10 is also responsible for the hyperfibrinolytic 
syndrome exhibited by patients with acute promyelocytic 
leukemia (APL). In this regard, S100A10 was shown to 
be regulated by the PML-RAR oncoprotein, the causative 
agent responsible for APL [34]. Collectively, these 
results suggest that the regulation of S100A10 by the 
oncogenes, PML-RAR and RAS plays an important role 
in oncogenesis.
Recent developments in cell capture technology 
have allowed, for the first time, the isolation of circulating 
tumor cells from cancer patients [82]. This approach 
facilitated identification of genes that are directly 
activated during the initial stages of metastasis, namely 
intravasation. Interestingly, this group reported the 
activation of the S100A10 gene during intravasation of 
breast cancer cells and showed that S100A10 was one of 
only 170 genes activated during this process. Furthermore, 
of all the well characterized plasminogen receptor genes, 
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only the S100A10 gene was identified in this analysis, 
in vivo. This study therefore highlighted S100A10 as a key 
gene that is activated during the early stages of metastasis. 
Our current study sheds new light on the role of S100A10 
in metastasis by demonstrating that oncogenic RAS 
activates the S100A10 gene and that S100A10 is critical 
for this RAS-dependent increases in cellular plasmin 
generation and invasiveness. 
MATERIALS AND METHODS
Cell culture, transfections and cell lines
MCF-7, MDA MB 231, HEK 293, Phoenix, A549, 
MiaPaca2, HT1080, HCT 116, NIH 3T3 and 293T 
cell lines were obtained from ATCC and maintained 
in Dulbecco’s modified Eagle’s medium (Hyclone) 
supplemented with 10% fetal bovine serum (FBS) and 
100 U/ml of penicillin/streptomycin, in a humidified 
incubator in an atmosphere of 5% CO
2
 at 37ºC. Cells 
were regularly tested for mycoplasma. For retrovirus 
production, Phoenix cells were transfected with 4 µg 
of the pBabe-puro HRAS V12 and HRAS loop mutants 
plasmids described below using 12 µl of L-lipofectamine 
2000 transfection reagent (Thermofisher) according to the 
manufacturers’ instructions. 48 hours after transfection the 
target cells were infected with Phoenix supernatants and 
selected with 2 µg/ml of puromycin. Cells were regularly 
tested for mycoplasma. A549 or MiaPaca2 cells plated in 
60 mm plates were transfected with 3 µg pKRAS-gRNA-
px459-V2 using 6 µl of jetPRIME reagent (Polyplus) 
according to the manufacturers’ instructions. 48 hours 
after transfection the cells were selected with 5 µg/ml 
of puromycin. Serial dilutions were performed to obtain 
A549 or MiaPaca2 KRAS subpopulations.
Plasmids
The plasmids pBabe-puro (Addgene # 1764) were a 
gift from Hartmut Land and Jay Morgenstern, pBabe-puro 
HRAS V12 (Addgene # 39526), were a gift from Julian 
Downward and HRAS V12 (Addgene #  9051) was a gift 
from William Hahn, pbabe - KRAS G12D (Addgene # 
58902) was a gift from Channing Der pBabe-puro 
HRAS V12 S35 (Addgene # 18746) was a gift from Jay 
Morgenstern, pBabe-puro HRAS V12 C40 (Addgene # 
18747) and pBabe-puro HRAS V12 G37 (Addgene # 
18745) was a gift from Scott Lowe S100A10 siRNA 
was purchased as a pre-designed sequence from Ambion 
(4392420). The pKRAS-gRNA1-px459-V2 plasmid was 
made by cloning the annealed oligos: 5′- CAC CGA ATA 
TAA ACT TGT GGT AGT-3′ and 5′-AAA CAC TAC CAC 
AAG TTT ATA TTC-3′ into px459-V2 from Addgene 
(62988) and the pKRAS-gRNA2-px459-V2 was made 
by cloning the annealed oligos: 5′-CAC CGA AAC TTG 
TGG TAG TTG GAG C-3′ and 5′-AAA CGC TCC AAC 
TAC CAC AAG TTT C-3′ into px459-V2 from Addgene. 
The pGL4.22- S100A10-promoter luciferase reporter 
plasmid was constructed by cutting the S100A10-promoter 
from the pCAT-S100A10-promoter plasmid and cloning it 
into the Kpn I/Sac I restriction sites of pGL4.22 vector 
(Promega). 
Antibodies
The following antibodies were used for western blot 
analysis: ANXA2 antibodies: 610069 (BD Transduction 
laboratories), D1/274.5 hybridoma (made in house); 
S100A10 antibodies: 610071 (BD Transduction laboratories), 
sc-81153 (SCBT); actin antibodies: (AC-40), A3853 
(SIGMA), sc-1615 (SCBT); β-tubulin antibody (H-235), 
sc-9104 (SCBT); HRAS antibody, sc-520 (SCBT), RAS 
antibody, clone RAS10, 05-516 (Millipore); KRAS antibody, 
H00003845-M01 (AbNova); H2B antibody, ab52599 
(Abcam); HMGB1 antibody, H9537 (Sigma); Cytokeratin 8 
antibody, ab53280 (Abcam); non-neuronal enolase antibody, 
ab54979 (Abcam); GAPDH antibody, sc-25778 (SCBT); 
uPAR antibody, 399R (American Diagnostica); ERK 1/2 
antibodies: sc-135900 (SCBT), 9102 (Cell Signaling); 
P-ERK 1/2 antibodies: 9101S (Cell Signaling), sc-377400 
(SCBT), ERK 1/2 antibody: sc-514302 (SCBT). The Plg RKT 
antibody was a kind gift from Dr. Lindsey Miles (Scripps 
Research Institute, San Diego, California). 
Western blot analysis
For western blot analysis, 20–25 μg of each cell 
lysate, unless noted otherwise, was subjected to SDS-
PAGE, transferred onto a nitrocellulose membrane, 
incubated with appropriate antibodies and visualized 
using a LI-COR Odyssey scanner (LI-COR Biosciences) 
or a ChemiDoc XRS+ system (Bio-Rad). Quantification 
of protein bands was done using the LI-COR Odyssey 
scanner software or Image J software as indicated in the 
figure legends. 
Elution of the S100A10-ANXA2 complex from 
the cell surface
Cells were incubated with PBS containing 20 mM 
EGTA in order to elute the cell surface bound S100A10-
ANXA2 heterotetramer (AIIt). The AIIt binds to the cell 
surface via calcium-dependent phospholipid binding 
domains existent in the ANXA2 moiety of the complex. 
Cells were centrifuged at 1000 g for 5 minutes and elutes 
containing cell surface S100A10 and ANXA2 were stored 
at -80°C. Cell pellets containing intracellular S100A10 
and ANXA2 were lysed. 20 µg of each total cell extract 
and equivalent amounts of each eluted sample were 
subjected to SDS-PAGE followed by western blotting with 
the antibodies indicated.
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FACS analysis
To assess the surface expression of S100A10 and 
ANXA2, cells were Fc blocked with rabbit IgG and then 
incubated with antibodies against S100A10 and ANXA2 
in PBS containing 1% FBS for 1 hour at 37°C, 5% CO
2
. 
Cells were washed two times with PBS containing Ca2+ 
and incubated with goat anti-mouse secondary antibody 
tagged with fluorescein isothiocyanate (FITC) (Sigma 
Aldrich) for 1 hour at 37°C, 5% CO
2
. Cells were washed 
two times with PBS containing Ca2+ and S100A10 and 
ANXA2 cell surface protein expression was analyzed by 
FACS, using a FITC filter. FACS data was analysed using 
the Winmdi software. 
qRT-PCR
RNA from cells transduced with empty vector 
retrovirus (pBabe), HRAS V12 or HRAS loop mutants 
expressing retroviruses was isolated by Trizol RNA 
extraction according to the manufacturer’s instructions. 
Briefly, each plate was gently washed with 300 µl of Trizol 
after which the Trizol/cell mixture was transferred onto 
an Eppendorf tube. 100 µl of chloroform was added to 
the tube, shaken vigorously for 15 seconds, and incubated 
for 10 minutes at room temperature. The resulting 
mixture was centrifuged at 12,000 × g for 15 minutes 
at 4°C. The aqueous phase was transferred onto a fresh 
tube and 250 µl of isopropanol was added. The tube was 
inverted a few times and incubated for 10 minutes at 
room temperature. After what samples were centrifuged 
at 12,000 × g for 10 minutes at 4°C. The RNA pellet was 
washed with 300 µl of 75 % ethanol and resuspended 
with 100 µl of MiliQ water. cDNA was generated using 
superscript II (Invitrogen) or NZY M-MuLV First-
Strand cDNA Synthesis Kit (Nzytech) according to the 
manufacturers´ instructions and the mRNA expression 
level for ANXA2, S100A10 or GAPDH was measured by 
qPCR using Quanti-fast Sybr Green Master mix (Qiagen) 
or NZYSpeedy qPCR Green Master Mix (2x) (Nzytech) 
according to the manufacturers´ instructions. The reaction 
was carried out using the MX3000P qRT-PCR machine 
or CFX96 Touch™ Real-Time PCR Detection System 
(Bio-Rad). The mRNA expression levels were normalized 
to GAPDH mRNA using the 2-ΔΔCT method (Livak KJ, 
Schmittgen TD) and are represented as ratio of RAS 
transformed over non-transformed cells. Error bars 
represent the standard deviation obtained from at least 
three independent experiments performed in triplicates. 
The following primers were used for qPCR: Human genes: 
ANXA2 Fwd: 5′-CTC TAC ACC CCC AAG TGC AT-3′; 
ANXA2 Rev: 5′-TCA GTG CTG ATG CAA GTT CC-
3′; S100A10 Fwd: 5′-AAA TTC GCT GGG GAT AAA 
GG-3′; S100A10 Rev: 5′-AGC CCA CTT TGC CAT CTC 
TA-3′; GAPDH Fwd: 5′-GAG TCA ACG GAT TTG GTC 
GT-3′; GAPDH Rev: 5′-TTG ATT TTG GAG GGA TCT 
CG-3′. Mouse genes: S100A10 Fwd: 5′-GAC CTG AGA 
GTG CTC ATG GA-3′; S100A10 Rev: 5′- CCG CCA CTA 
GTG ATA GAA AGC-3′; ANXA2 Fwd: 5′- CAG CAG 
TCA AGA CCA AAG GA-3′; ANXA2 Rev: 5′- GGC 
CAG ATA AGG CTG ACT TC-3′; GAPDH Fwd: 5′- ACA 
ACT TTG GCA TTG TGG AA-3′; GAPDH Rev: 5′- GAT 
GCA GGG ATG ATG TTC TG-3′.
Plasmin activation assay
Cells were plated in 96 wells plate and washed three 
times with incubation buffer (Hanks balanced salt solution 
containing 3 mM CaCl
2
 and 1 mM MgCl
2
) Cells were then 
incubated with 0.5 µM glu-plasminogen with or without 
the plasmin inhibitors, aprotinin (2.2 µM, Pentapharm) 
or ε-aminocaproic acid (ε-ACA) (100 mM, synthetic 
inhibitor of the plasminogen system, SIGMA) or CpB 
(5 U/ml, SIGMA) or the broad specificity MMP inhibitor 
GM6001 (25 µM, Millipore), for 10 minutes before the 
addition of 250 µM plasmin chromogenic substrate, S2251 
(Chromogenix, Diapharma Group). Plasmin activity 
was measured spectrophotometrically (405 nm) taking 
readings every minute for 2 hours. N = 6. Time course 
data are analyzed according to the equation describing 
the rate of p-nitroanilide (p-NA) production A405 nm = B 
+ Kt2, where K is the rate constant for the acceleration 
of p-NA generation and B is the y-intercept. Under our 
experimental conditions, K is proportional to the initial 
rate of plasmin formation from plasminogen. 
Invasion/migration assays
105 cells were plated on the upper chamber of 
Matrigel (MTG)-coated chambers (BD Biosciences) 
(invasion) or non-coated chambers (migration) and 
incubated in serum free medium containing 0.5 μM 
glu-plasminogen, with or without the plasmin inhibitor 
aprotinin, or ε-amino caproic acid (ε-ACA) or the broad 
specificity MMP inhibitor GM6001. Alternatively, some 
cells were also incubated with carboxypeptidase B (CpB) 
before plating as described previously [83]. The lower 
chamber contained medium with 10% fetal bovine serum 
(FBS), as a chemoattractant. Cells were incubated at 37°C 
and 5%CO
2
 for 24 hours. Invading cells were quantified 
according to the manufacturer’s instructions. Data are 
expressed as mean number of cells per 40X field (10 
fields/experimental condition) plus or minus StdDev of 4 
independent wells. Statistical analysis was performed using 
the Student t test or using two-way ANOVA as indicated.
Promoter assays
Cells were co-transfected with S100A10 full-
length promoter in pGL4.22 backbone and pRSV-Renilla 
(transfection control) at a ratio of 50:1. Luciferase 
promoter assay was performed according to the 
manufacturer’s instructions (Dual Luciferase promoter 
assay, Promega). Error bars represent the standard 
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deviation obtained from five independent experiments 
with at least triplicate samples each.
Depletion of S100A10 in HRAS V12 expressing cells
Pre-designed S100A10 siRNA sequences and a 
siRNA non-silencing control was transfected in pBabe–
puro and HRAS V12 stable cell lines using lipofectamine 
2000 transfection reagent according to the manufacturer’s 
instructions (Invitrogen). Plasmin activity and invasion 
assays were performed 48 hours after transfection as 
described above. Statistical analysis was performed using 
two-way ANOVA with Tukey test of significance.
Statistical analysis
Statistical significance was determined by Student’s 
t test or two-way ANOVA. Results were considered 
significant if 2-tailed P values were less than 0.05. All data 
are expressed as mean ± StdDev.
ACKNOWLEDGMENTS
This work was supported by a grant from the 
Canadian Institutes of Health Research (CIHR) MOP-
274028 (DMW) ) and a research grant from Fundação 
para a Ciência e a Tecnologia (FCT), Portugal, ref: 
IF/00614/2014/CP12340006 (PAM). Alamelu Bharadwaj 
(AGB) and Moamen Bydoun (MB) are supported by 
training awards from the Beatrice Hunter Cancer Research 
Institute with funds provided by the Harvey Graham 
Cancer Research Fund as part of The Terry Fox Strategic 
Health Research Training Program in Cancer Research at 
CIHR. Patrícia A Madureira (PAM) is supported by an FCT 
Investigator contract, ref: IF/00614/2014 from Fundação 
para a Ciência e a Tecnologia, Portugal. The authors 
acknowledge the helpful assistance of Ms. Victoria Miller 
in compiling data and in the editing of the manuscript.
CONFLICTS OF INTEREST
The authors declare no conflicts of interests.
Author contributions
Conceived and designed the experiments: PAM, 
AGB, KG, PAO, PL, DMW. Performed the experiments: 
PAM, AGB, MB, PAO. Analyzed the data: PAM, AGB, MB, 
PAO, PL, DMW. Wrote the paper: PAM, AGB and DMW.
REFERENCES
1. Bergman BL, Scott RW, Bajpai A, Watts S, Baker JB. 
Inhibition of tumor-cell-mediated extracellular matrix 
destruction by a fibroblast proteinase inhibitor, protease 
nexin I. Proc. Natl. Acad. Sci. USA. 1986; 83:996–1000. 
 2. Bogenrieder T, Herlyn M. Axis of evil: molecular 
mechanisms of cancer metastasis. Oncogene. 2003; 
22:6524–6536. 
 3. Ossowski L. Plasminogen activator dependent pathways 
in the dissemination of human tumor cells in the chick 
embryo. Cell. 1988; 52:321–328. 
 4. Ossowski L. In vivo invasion of modified chorioallantoic 
membrane by tumor cells: the role of cell surface-bound 
urokinase. J. Cell Biol. 1988; 107:2437–2445. 
 5. Saiki I, Naito S, Yoneda J, Azuma I, Price JE, Fidler IJ. 
Characterization of the invasive and metastatic phenotype 
in human renal cell carcinoma. Clin Exp Metastasis. 1991; 
9:551–66. 
 6. Kwaan HC. The plasminogen-plasmin system in 
malignancy. [Review]. Cancer Metastasis Rev. 1992; 
11:291–311. 
 7. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, 
Lambert V, Foidart JM, Noel A. Role of plasminogen 
activator-plasmin system in tumor angiogenesis. Cell Mol 
Life Sci. 2003; 60:463–473. 
 8. Mohamed MM, Sloane BF. Cysteine cathepsins: 
multifunctional enzymes in cancer. Nat. Rev. Cancer. 2006; 
6:764–775. 
 9. Stamenkovic I. Matrix metalloproteinases in tumor invasion 
and metastasis. Semin Cancer Biol. 2000; 10:415–33. 
10. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The 
urokinase-type plasminogen activator system in cancer 
metastasis: A review. Int J Cancer. 1997; 72:1–22. 
11. Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, 
Botkjaer KA, Andreasen PA, Quigley JP. Activation of pro-
uPA is critical for initial escape from the primary tumor and 
hematogenous dissemination of human carcinoma cells. 
Neoplasia. 2011; 13:806–21. 
12. Blouse GE, Bøtkjaer KA, Deryugina E, Byszuk AA, 
Jensen JM, Mortensen KK, Quigley JP, Andreasen PA. A novel 
mode of intervention with serine protease activity: targeting 
zymogen activation. J Biol Chem. 2009; 284:4647–57. 
13. Sidenius N, Blasi F. The urokinase plasminogen activator 
system in cancer: recent advances and implication for 
prognosis and therapy. Cancer Metastasis Rev. 2003; 
22:205–22. 
14. Duffy MJ. The urokinase plasminogen activator system: 
role in malignancy. Curr Pharm Des. 2004;10:39–49. 
15. Duffy MJ, Duggan C. The urokinase plasminogen 
activator system: a rich source of tumour markers for the 
individualised management of patients with cancer. Clin 
Biochem. 2004; 37:541–548. 
16. Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-
Hansen G. uPAR as Anti-Cancer Target: Evaluation of 
Biomarker Potential, Histological Localization, and Antibody-
Based Therapy. Curr Drug Targets 2011; 12:1744-60 
17. Manders P, Tjan-Heijnen VCG, Span PN, Grebenchtchikov N, 
Geurts-Moespot A, van Tienoven DTH, Beex LVAM, Sweep 
FCGJ. Complex of urokinase-type plasminogen activator 
Oncotarget47735www.impactjournals.com/oncotarget
with its type 1 inhibitor predicts poor outcome in 576 patients 
with lymph node-negative breast carcinoma. Cancer. 2004; 
101:486–94. 
18. Bonnefoy A, Legrand C. Proteolysis of subendothelial 
adhesive glycoproteins (fibronectin, thrombospondin, and 
von Willebrand factor) by plasmin, leukocyte cathepsin G, 
and elastase. ThrombRes. 2000; 98:323–332. 
19. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, 
Nielsen LS, Skriver L. Plasminogen activators, tissue 
degradation, and cancer. [Review]. Adv Cancer Res. 1985; 
44:139–266. 
20. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, 
Lund LR, Ploug M, Romer J. Plasminogen activation and 
cancer. Thromb Haemost. 2005; 93:676–81. 
21. Lijnen HR. Plasmin and matrix metalloproteinases in 
vascular remodeling. Thromb Haemost. 2001; 86:324–33. 
22. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, 
Garbisa S, Mignatti P. Control of type IV collagenase 
activity by components of the urokinase-plasmin system: a 
regulatory mechanism with cell-bound reactants. EMBO J. 
1997; 16:2319–2332. 
23. Felez J. Plasminogen binding to cell surfaces. Fibrinolysis 
& Proteolysis. 1998; 12:183–9. 
24. Kwon M, MacLeod TJ, Zhang Y, Waisman DM. S100A10, 
annexin A2, and annexin A2 heterotetramer as candidate 
plasminogen receptors. Front Biosci. 2005; 10:300–325. 
25. Miles LA, Parmer RJ. Plasminogen receptors: the first 
quarter century. Semin Thromb Hemost. 2013; 39:329–37. 
26. Miles LA, Hawley SB, Baik N, Andronicos NM, 
Castellino FJ, Parmer RJ. Plasminogen receptors: the 
sine qua non of cell surface plasminogen activation. Front 
Biosci. 2005; 10:1754–1762. 
27. Miles LA, Plow EF, Waisman DM, Parmer RJ. Plasminogen 
receptors. J Biomed Biotechnol. 2012; 2012:130735. 
28. Plow EF, Freaney DE, Plescia J, Miles LA. The 
plasminogen system and cell surfaces: evidence for 
plasminogen and urokinase receptors on the same cell type. 
J Cell Biol. 1986;103:2411–20. 
29. Kassam G, Le BH, Choi KS, Kang HM, Fitzpatrick SL, 
Louie P, Waisman DM. The p11 subunit of the annexin 
II tetramer plays a key role in the stimulation of t-PA-
dependent plasminogen activation. Biochemistry. 1998; 
37:16958–66. 
30. Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, 
Zackson T, Zackson S, Toba M, Shinomiya A, Waisman DM. 
The role of annexin II tetramer in the activation of 
plasminogen. J Biol Chem. 1998; 273:4790–4799. 
31. Choi KS, Fogg DK, Yoon CS, Waisman DM. P11 regulates 
extracellular plasmin production and invasiveness of 
HT1080 fibrosarcoma cells. FASEB J. 2003; 17:235–246. 
32. Zhang L, Fogg DK, Waisman DM. RNA interference-
mediated silencing of the S100A10 gene attenuates plasmin 
generation and invasiveness of Colo 222 colorectal cancer 
cells. J Biol Chem. 2004; 279:2053–2062. 
33. Madureira PA, O’Connell PA, Surette AP, Miller VA, 
Waisman DM. The Biochemistry and Regulation of 
S100A10: A Multifunctional Plasminogen Receptor 
Involved in Oncogenesis. J Biomed Biotechnol. 2012; 
2012:353687. 
34. O’Connell PA, Madureira PA, Berman JN, Liwski RS, 
Waisman DM. Regulation of S100A10 by the PML-RAR-α 
oncoprotein. Blood. 2011; 117:4095–105. 
35. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. 
Targeted disruption of the K-ras oncogene in an invasive 
colon cancer cell line down-regulates urokinase receptor 
expression and plasminogen- dependent proteolysis. Br J 
Cancer. 1999; 80:1884–1891. 
36. Testa JE, Medcalf RL, Cajot JF, Schleuning WD, Sordat B. 
Urokinase-type plasminogen activator biosynthesis is 
induced by the EJ-Ha-ras oncogene in CL26 mouse colon 
carcinoma cells. Int J Cancer. 1989; 43:816–22. 
37. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS 
oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 
2011; 11:761–74. 
38. Cavallo-Medved D, Dosescu J, Linebaugh BE, Sameni M, 
Rudy D, Sloane BF. Mutant K-ras regulates cathepsin B 
localization on the surface of human colorectal carcinoma 
cells. Neoplasia. 2003; 5:507–519. 
39. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, 
Boyd D. Stimulation of 92-kDa gelatinase B promoter 
activity by ras is mitogen-activated protein kinase kinase 
1-independent and requires multiple transcription factor 
binding sites including closely spaced PEA3/ets and AP-1 
sequences. J Biol Chem. 1996; 271:10672–10680. 
40. Ceruti P, Principe M, Capello M, Cappello P, Novelli F. 
Three are better than one: plasminogen receptors as cancer 
theranostic targets. Exp Hematol Oncol. 2013; 2:12. 
41. Kumari S, Malla R. New Insight on the Role of Plasminogen 
Receptor in Cancer Progression. Cancer Growth Metastasis. 
2015; 8:35–42. 
42. Felez J, Chanquia CJ, Levin EG, Miles LA, Plow EF. 
Binding of tissue plasminogen activator to human monocytes 
and monocytoid cells. Blood. 1991; 78:2318–2237. 
43. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, 
Plow EF. Role of cell-surface lysines in plasminogen 
binding to cells: identification of alpha-enolase as a 
candidate plasminogen receptor. Biochemistry. 1991; 
30:1682–1691. 
44. Ehinger S, Schubert WD, Bergmann S, Hammerschmidt S, 
Heinz DW. Plasmin(ogen)-binding alpha-enolase from 
Streptococcus pneumoniae: crystal structure and evaluation of 
plasmin(ogen)-binding sites. J Mol Biol. 2004; 343:997–1005. 
45. Parkkinen J, Rauvala H. Interactions of plasminogen and 
tissue plasminogen activator (t- PA) with amphoterin. 
Enhancement of t-PA-catalyzed plasminogen activation by 
amphoterin. J Biol Chem. 1991; 266:16730–16735. 
46. Miles LA, Levin EG, Plescia J, Collen D, Plow EF. 
Plasminogen receptors, urokinase receptors, and their 
Oncotarget47736www.impactjournals.com/oncotarget
modulation on human endothelial cells. Blood. 1988; 
72:628–635. 
47. Andronicos NM, Ranson M, Bognacki J, Baker MS. The 
human ENO1 gene product (recombinant human alpha-
enolase) displays characteristics required for a plasminogen 
binding protein. BiochimBiophysActa. 1997; 1337:27–39. 
48. Gonias SL, Hembrough TA, Sankovic M. Cytokeratin 8 
functions as a major plasminogen receptor in select epithelial 
and carcinoma cells. Front Biosci. 2001; 6:D1403–1411. 
49. Hembrough TA, Vasudevan J, Allietta MM, Glass WF, 
Gonias SL. A cytokeratin 8-like protein with plasminogen-
binding activity is present on the external surfaces of 
hepatocytes, HepG2 cells and breast carcinoma cell lines. 
J Cell Sci. 1995; 108:1071–1082. 
50. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, 
Baumann M, Rauvala H. Amphoterin, the 30-kDa protein 
in a family of HMG1-type polypeptides. Enhanced 
expression in transformed cells, leading edge localization, 
and interactions with plasminogen activation. J Biol Chem. 
1993; 268:19726–19738. 
51. Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, 
Miles LA. Regulation of Macrophage Migration by a Novel 
Plasminogen Receptor Plg-RKT. Blood. 2011; 118:5622–5630. 
52. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, 
Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V. 
Metastasis-associated protein S100A4 induces angiogenesis 
through interaction with Annexin II and accelerated plasmin 
formation. J Biol Chem. 2005; 280:20833–20841. 
53. Herren T, Burke TA, Das R, Plow EF. Identification 
of histone H2B as a regulated plasminogen receptor. 
Biochemistry. 2006; 45:9463–9474. 
54. Gires O, Andratschke M, Schmitt B, Mack B, Schaffrik M. 
Cytokeratin 8 associates with the external leaflet of 
plasma membranes in tumour cells. Biochem Biophys Res 
Commun. 2005; 328:1154–1162. 
55. Godfroid E, Geuskens M, Dupressoir T, Parent I, Szpirer C. 
Cytokeratins are exposed on the outer surface of established 
human mammary carcinoma cells. J Cell Sci. 1991; 
99:595–607. 
56. Kuchma MH, Kim JH, Muller MT, Arlen PA. Prostate 
cancer cell surface-associated keratin 8 and its implications 
for enhanced plasmin activity. Protein J. 2012; 31:195–205. 
57. Diaz-Guerra M, Haddow S, Bauluz C, Jorcano JL, 
Cano A, Balmain A, Quintanilla M. Expression of simple 
epithelial cytokeratins in mouse epidermal keratinocytes 
harboring Harvey ras gene alterations. Cancer Res. 1992; 
52:680–687. 
58. Fortier A-M, Asselin E, Cadrin M. Keratin 8 and 18 loss 
in epithelial cancer cells increases collective cell migration 
and cisplatin sensitivity through claudin1 up-regulation. 
J Biol Chem. 2013; 288:11555–11571. 
59. Bharadwaj A, Bydoun M, Holloway R, Waisman D. 
Annexin A2 heterotetramer: structure and function. Int J 
Mol Sci. 2013; 14:6259–6305. 
60. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, 
Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, 
Coloff JL, Yan H, Wang W, Chen S, et al. Oncogenic 
Kras Maintains Pancreatic Tumors through Regulation of 
Anabolic Glucose Metabolism. Cell. 2012; 149:656–670. 
61. White MA, Nicolette C, Minden A, Polverino A, Van 
Aelst L, Karin M, Wigler MH. Multiple Ras functions can 
contribute to mammalian cell transformation. Cell. 1995; 
80:533–41. 
62. Eckert LB, Repasky GA, Ulkü AS, McFall A, Zhou H, 
Sartor CI, Der CJ. Involvement of Ras activation in human 
breast cancer cell signaling, invasion, and anoikis. Cancer 
Res. 2004 ;64:4585–4592. 
63. Diaz-Flores E, Shannon K. Targeting oncogenic Ras. Genes 
Dev. 2007;  21:1989–1992. 
64. Jankun J, Maher VM, McCormick JJ. Malignant 
Transformation of Human Fibroblasts Correlates with 
Increased Activity of Receptor-bound Plasminogen 
Activator. Cancer Research. 1991; 51:1221–1226. 
65. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a 
mitogen-activated protein kinase signaling pathway in the 
regulation of urokinase promoter activity by c-Ha- ras. J 
Biol Chem. 1995; 270:23007–23012. 
66. Muller SM, Okan E, Jones P. Regulation of urokinase 
receptor transcription by Ras- and Rho-family GTPases. 
Biochem Biophys Res Commun. 2000; 270:892–898. 
67. Silberman S, Janulis M, Schultz RM. Characterization of 
downstream Ras signals that induce alternative protease-
dependent invasive phenotypes. J Biol Chem. 1997; 
272:5927–5935. 
68. Westermarck J, Kähäri VM. Regulation of matrix 
metalloproteinase expression in tumor invasion. FASEB J. 
1999; 13:781–792. 
69. Axelrod JH, Reich R, Miskin R. Expression of human 
recombinant plasminogen activators enhances invasion and 
experimental metastasis of H-ras-transformed NIH 3T3 
cells. Mol Cell Biol. 1989; 9:2133–2141. 
70. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, 
Pappin D, Das P, Waterfield MD, Ridley A, Downward J. 
Role of phosphoinositide 3-OH kinase in cell transformation 
and control of the actin cytoskeleton by Ras. Cell. 1997; 
89:457–467. 
71. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, 
Kelly K. Signal pathways which promote invasion and 
metastasis: critical and distinct contributions of extracellular 
signal-regulated kinase and Ral-specific guanine exchange 
factor pathways. Mol Cell Biol. 2001; 21:5958–5969. 
72. MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. 
Phospholipid-associated annexin A2-S100A10 
heterotetramer and its subunits: characterization of the 
interaction with tissue plasminogen activator, plasminogen, 
and plasmin. J Biol Chem. 2003; 278:25577–25584. 
73. Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, 
Sugiyama T, Takayama T, Mugiya S, Ozono S, Nozawa R. 
Oncotarget47737www.impactjournals.com/oncotarget
Evaluation of S100A10, annexin II and B-FABP expression 
as markers for renal cell carcinoma. Cancer Sci. 2007; 
98:77–82. 
74. Ito Y, Arai K, Nozawa R, Yoshida H, Higashiyama T, 
Takamura Y, Miya A, Kobayashi K, Kuma K, Miyauchi A. 
S100A10 expression in thyroid neoplasms originating from 
the follicular epithelium: contribution to the aggressive 
characteristic of anaplastic carcinoma. Anticancer Res. 
2007; 27:2679–2683. 
75. Johansson HJ, Sanchez BC, Forshed J, Stål O, Fohlin H, 
Lewensohn R, Hall P, Bergh J, Lehtiö J, Linderholm BK. 
Proteomics profiling identify CAPS as a potential predictive 
marker of tamoxifen resistance in estrogen receptor positive 
breast cancer. Clin Proteomics. 2015; 12:8. 
76. Korwar AM, Bhonsle HS, Ghole VS, Gawai KR, 
Koppikar CB, Kulkarni MJ. Proteomic profiling and 
interactome analysis of ER-positive/HER2/neu negative 
invasive ductal carcinoma of the breast: towards proteomics 
biomarkers. OMICS. 2013; 17:27–40. 
77. Ma X-J, Salunga R, Tuggle JT, Gaudet J, Enright E, 
McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, 
Zhou Y-X, Varnholt H, Smith B, et al. Gene expression 
profiles of human breast cancer progression. Proc Natl Acad 
Sci USA. 2003; 100:5974–5979. 
78. Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, 
Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, 
Davidson B. Expression and clinical role of chemoresponse-
associated genes in ovarian serous carcinoma. Gynecol 
Oncol. 2015; 139:30-39. 
79. Shang X, Sun J, He Y, Zhao W, Li Q, Zhou F, Chen B, 
Cheng H, Zhou R. Identification and predominant expression 
of annexin A2 in epithelial-type cells of the rice field eel. 
Journal of Cellular Biochemistry. 2007; 101:600–608. 
80. Sitek B, Sipos B, Alkatout I, Poschmann G, Stephan C, 
Schulenborg T, Marcus K, Lüttges J, Dittert D-D, 
Baretton G, Schmiegel W, Hahn SA, Klöppel G, et al. 
Analysis of the pancreatic tumor progression by a 
quantitative proteomic approach and immunhistochemical 
validation. J Proteome Res. 2009; 8:1647–1656. 
81. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, 
Thorgeirsson SS. Inactivation of Ras GTPase-activating 
proteins promotes unrestrained activity of wild-type Ras in 
human liver cancer. J Hepatol. 2011; 54:311–319. 
82. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, 
Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, 
Concannon KF, Donaldson MC, Sequist LV, et al. 
Circulating breast tumor cells exhibit dynamic changes in 
epithelial and mesenchymal composition. Science. 2013; 
339:580–584. 
83. O’Connell PA, Surette AP, Liwski RS, Svenningsson P, 
Waisman DM. S100A10 regulates plasminogen-dependent 
macrophage invasion. Blood. 2010; 116:1136–46. 
